DRG 828 Overview

DRG 828 covers hospital admissions for patients with myeloproliferative disorders or poorly differentiated neoplasms who undergo major operating room procedures and do not have a Complication or Comorbidity or a Major Complication or Comorbidity. This Diagnosis-Related Group groups cases by clinical complexity tied to surgical intervention rather than medical comorbidity, which affects relative resource use and payment. It matters for Medicare payment because assignment to this Diagnosis-Related Group determines the base prospective payment and influences hospital revenue for operative oncology and hematology admissions. Accurate coding of diagnoses and procedures is essential to ensure correct Diagnosis-Related Group assignment and reimbursement.

• Trials assessing perioperative and intraoperative management strategies for patients with myeloproliferative disorders or poorly differentiated neoplasms undergoing major operative procedures: these studies evaluate protocols such as blood product management, thrombosis prophylaxis, and timing of cytoreductive therapy around surgery in a predominantly inpatient surgical population. The focus population includes adults with active myeloproliferative neoplasms or poorly differentiated hematologic malignancies who require major OR procedures, and the research question is how to minimize surgical complications (bleeding, thrombosis, infection) and length of stay. Results inform hospital clinicians and payers about best-practice perioperative pathways that can reduce resource utilization and readmissions for this high-risk DRG group.
• Comparative effectiveness studies of different inpatient procedural approaches and supportive care bundles for cytoreductive or marrow-directed major procedures: these studies compare outcomes of alternative operative techniques, anesthesia strategies, or bundled supportive measures (e.g., standardized transfusion thresholds, antimicrobial prophylaxis, and ICU admission criteria) in patients with myeloproliferative disorders or poorly differentiated neoplasms without major complication codes. The population includes surgical inpatients whose primary diagnosis falls into this DRG and the objective is to identify which approaches yield better short-term clinical outcomes, lower complication rates, and more efficient use of inpatient resources. Findings help providers choose cost-effective care pathways and help payers predict expected resource needs and appropriate reimbursement for similar episodes.
• Post-discharge and outcomes research on readmission risk, functional recovery, and long-term hematologic control after major OR procedures: these observational cohort studies track patients discharged after major surgery to determine drivers of 30- and 90-day readmissions, impacts of perioperative oncology management on disease progression, and functional status recovery in survivors of myeloproliferative disorders or poorly differentiated neoplasms. The patient group comprises those assigned to this DRG who survive hospitalization and require ongoing hematology-oncology follow-up; the research identifies modifiable factors (transition-of-care processes, outpatient hematology access, rehabilitation needs) that influence downstream utilization. Such evidence is valuable for hospitals and payers aiming to reduce readmissions, allocate post-acute services appropriately, and tie inpatient episode payments to longer-term outcomes.